Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LV-TYRP1
- Development stage
- Preclinical
- Lead developer
- Wenzhou Medical University
- Modality
- Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravitreal
01
Overview
LV-TYRP1 is an experimental gene therapy construct consisting of a lentiviral vector (LV) designed to deliver and overexpress the Tyrosinase-related protein 1 (TYRP1) gene. In preclinical research, particularly studies focusing on glaucoma and retinal health, TYRP1 has been identified as a protective factor for retinal ganglion cells (RGCs). The mechanism involves TYRP1 binding to premelanosome protein (PMEL), which subsequently mitigates oxidative stress and inhibits apoptosis in RGCs under conditions of chronic ocular hypertension. By utilizing a lentiviral delivery system, researchers aim to achieve stable expression of TYRP1 to evaluate its potential as a neuroprotective treatment for glaucomatous neurodegeneration.
- Other names
- Lentiviral-TYRP1Lentiviral-TYRP-1Lentiviral-TYRP 1Lentivirus-TYRP1Lentivirus-TYRP-1Lentivirus-TYRP 1Lentiviral vector expressing TYRP1
02
Targets
TYRP1 (Tyrosinase-related protein 1)
Beyond the preview
Go deeper on LV-TYRP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LV-TYRP1.